EKElizaveta E. Klebanova

Elizaveta E. Klebanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizaveta E. Klebanova has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical observation of thrombotic thrombocytic purpura (TTP) during pregnancy: an algorithm and life-saving differential diagnosis

    by R.G. Shmakov, A.V. Pyregov, G.N. Karimova, T.S. Kovalenko, A.A. Travkina, T.S. Budykina, M.M. Blazhko, O.V. Chaplygina, E.E. Klebanova, G.M. Galstyan, et al.

    Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathic disorder characterized by severe thrombocytopenia, microangiopathic hemolysis, and multiorgan dysfunction. In obstetric practice, TTP often mimics severe forms of preeclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, thrombocytopenia), leading to diagnostic errors and delays in treatment. This article presents the case of a young primiparous patient who, at 38 weeks of gestation, developed clinical features consistent with HELLP syndrome and was diagnosed with ADAMTS13 deficiency. This allowed for the confirmation of the diagnosis of TTP and prompt modification of treatment.

  • Open Access

    Congenital thrombotic thrombocytopenic purpura in adults: Manifestations and treatment

    by G. M. Galstyan, E. E. Klebanova, Y. M. Poznyakova, O. S. Pshenichnikova, S. Yu. Mamleeva, N. V. Purlo, N. G. Ipatova, V. L. Surin, Ю. М. Познякова

    Introduction. Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare thrombotic microangiopathy that occurs due to a congenital deficiency of the ADAMTS13 enzyme. It can manifest both in childhood and in adulthood. Aim: to analyze the manifestations and course of cTTP in adult patients. Materials and methods. Hemoglobin and platelet concentrations, a direct Coombs test, lactate dehydrogenase (LDH), ADAMTS13 activity, and ADAMTS13 inhibitor were studied in patients with suspected thrombotic thrombocytopenic purpura (TTP). In patients with ADAMTS13 activity< 10% and the absence of an ADAMTS13 inhibitor, the concentration of the ADAMTS13 antigen and mutations of the ADAMTS13 gene were studied. cTTP was diagnosed in the absence of ADAMTS13 inhibitor and the detection of mutations in ADAMTS13 gene. Results. cTTP was diagnosed in 11 (9.5 %) patients (10 women, 1 man) among 115 adult patients with TTP. Mutations of ADAMTS13 gene were detected in all patients. Disease onset occurred between the ages of 20 and 33 years 33 (median 22 years). In 9 out of 10 women, the onset of the disease was associated with pregnancy. During TTP manifestation all patients had thrombocytopenia ((4–31)×109 /L, median 14×109 /L), anemia (hemoglobin 67 g/L), increased LDH activity (median 1300 U/L), low ADAMTS13 activity (median 2 %), and low ADAMTS13 antigen concentration (median 0.008 IU/ml). Neurological symptoms were present in 5 (45 %) of the 11 patients, and 2 of the 11 patients developed chronic renal failure. In clinical remission, all patients had normal ranges of hemoglobin, platelets and LDH activity, however ADAMTS13 activity remained low (0–18 %, median 7.5 %). Treatment during exacerbation included plasma transfusions; 8 patients underwent plasma exchange. Prophylactically, most patients received plasma at a dose of 15 mL/kg every 3–4 weeks. Three patients were treated with recombinant ADAMTS13 at a dose of 40 IU/kg intravenously once every 2 weeks. The therapy was well tolerated, and there was an increase of platelet level after drug administration. Conclusion . cTTP can manifest in adulthood. In remission, cTTP patients need laboratory monitoring and preventive treatment.

  • Open Access

    Personalised treatment of patients with immune thrombotic thrombocytopenic purpura

    by Gennady M. Galstyan, Elizaveta E. Klebanova, Svetlana Yu. Mamleeva, Pavel V. Avdonin, Zalina T. Fidarova, Mikhail Yu. Drokov, Elena N. Parovichnikova

    Background. Treatment of immune thrombotic thrombocytopenic purpura (iTTP) includes plasma exchange (PEX) and immunosuppression (glucocorticoids and rituximab). The addition of caplacizumab to therapy has improved treatment outcomes in iTTP. However, the available therapies focus on the duration of drug administration and clinical response rather than ADAMTS13 activity. Aim. To evaluate the efficacy of therapy for iTTP targeting ADAMTS13 activity. Materials and methods. Treatment of patients with iTTP was started with PEX, prednisolone (1 mg/kg) and caplacizumab (10 mg/day). PEX was discontinued after an increase of platelet count 150×109/L. Only after PEX cessation treatment with rituximab (375 mg/m2 weekly) was started. Caplacizumab was discontinued when partial remission (ADAMTS13 20%) was achieved. Rituximab and glucocorticoids were discontinued when complete remission (ADAMTS13 40%) was achieved. Platelet count, schistocyte count, haemoglobin, haptoglobin, lactate dehydrogenase activity, ADAMTS13, ADAMTS13 inhibitor titre, number of PEX, plasma volume replaced, time to increase platelet count 150×109/L, achievement of partial and complete remission were analyzed. Data are presented as median and interquartile range. Results. From 2021 to 2025, the diagnosis of TTP was confirmed in 102 patients. 35 patients were included in the study. Platelet counts 150×109/L were achieved after 4 (3–5) PEX procedures in 4 (3–4.5) days. In total, 11 395 (7241–16 343) ml of plasma were exchanged. Partial remission was achieved in 100% of patients, the duration of caplacizumab therapy was 23 (12–30) days. Rituximab was administered from 4 to 8 times (median 4), complete remission was achieved in 33 out of 35 patients, 2 patients achieved only partial remission, they were treated with bortezomib and 1 with anti-CD38 monoclonal antibody. The probability of complete remission was 97.1%. Conclusion. The duration of therapy with caplacizumab, rituximab and glucocorticoids in patients with iTTP should be determined by the achievement of target ADAMTS13 activity.


  • Open Access

    Successful Treatment of Refractory Immune Thrombotic Thrombocytopenic Purpura with Daratumumab

    by E. E. Klebanova, Gennadii Martinovich Galstyan, S. Yu. Mamleeva, D. K. Bessmertnyy, Z. T. Fidarova, E. N. Parovichnikova

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare life-threatening disease manifested by thrombocytopenia, microangiopathic hemolytic anemia, and impaired functions of organs and systems due to the thrombosis of small arteries. The basis of the disease lies in the production of autoantibodies that eliminate or inhibit the activity of metalloproteinase ADAMTS13 (A Disintegrin and Metalloprotease with ThromboSpondin type 1 repeats, member 13). ADAMTS13 is one of the plasma proteins that cleave the high-molecular-weight von Willebrand factor. The standard iTTP treatment includes therapeutic plasma exchange, caplacizumab administration, and immunosuppressive therapy with glucocorticoids and rituximab. The present paper documents the first case report in Russia demonstrating the effective use of daratumumab in a 51-year-old female patient with refractory iTTP. The disease manifested with hemolytic anemia and deep thrombocytopenia with pronounced neurological disorders. The ADAMTS13 activity was 0 %, ADAMTS13 inhibitor titer was 3 units by Bethesda. As a result of the standard triplet therapy followed by addition of bortezomib, the thrombocyte count returned to normal, hemolysis ceased, and neurological symptoms regressed. At the same time, the hematological analysis showed zero activity of ADAMTS13 as well as persistent plasma protein inhibitor. The absence of this inhibitor and an increase of ADAMTS13 activity to 45 %, which correspond to complete iTTP remission, were achieved only after daratumumab administration. The paper comprehensively discusses the central features of the clinical case report and possible action mechanisms of various drugs used for the treatment of this life-threatening disease.

  • Open Access

    How I treat thrombotic thrombocytopenic purpura

    by G. M. Galstyan, E. E. Klebanova, S. Yu. Mamleeva

    Introduction. Thrombotic thrombocytopenic purpura (TTP) is a rare disease manifested by non-immune thrombocytopenia, microangiopathic hemolytic anemia and organ and system dysfunction.Aim: to present the scheme of treatment of a patient with TTP.Main findings. The case report of a 32-years-old patient, in whom TTP manifested with anemia, thrombocytopenia, and ischemic stroke, is presented. The patient was successfully treated with plasma exchange, prednisolone, caplacizumab, rituximab. Diagnostic errors, logic of prescription and cancellation of these or those drugs are discussed.

  • Open Access

    How I treat peripheral T-cell lymphomas

    by L. G. Gorenkova, Ya. K. Mangasarova, A. M. Kovrigina, S. K. Kravchenko, E. E. Klebanova, M. O. Bagova, Yu. A. Chabaeva, O. V. Margolin, E. E. Zvonkov

    Introduction. Peripheral T-cell lymphomas (PTCL) — a rare group of lymphoproliferative diseases characterized by an aggressive course and an unfavorable prognosis. The group is represented by heterogeneous nosological forms, in which standard treatment options lead to unsatisfactory results. Aim: to present the protocols for the treatment of PTCLMain findings. In total, 12 years of experience in the treatment of 724 patients with T-cell lymphomas (430 patients with primary cutaneous forms, 110 patients with leukemic variants and 184 with peripheral T-cell lymphomas) has been accumulated. The treatment results and therapeutic algorithms were analyzed. In the general group of patients, the 3-year overall survival (OS) and relapse-free survival (EFS) were 76 % and 70 %, respectively. The best treatment results were achieved in the groups of intestinal T-cell lymphoma, specifically (EATL), and angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell ALK-positive lymphoma (ALCL ALK+), and the worst — in the group of ALCL ALK- (5-year EFS 31 %). High-dose chemotherapy under the NHL BFM-90 program in the treatment of ALK+ ALCL allows achieving 10-year OS and EFS 87 % and 84 %, respectively, but the less toxic CHOEP program was not inferior in effectiveness: 5-year OS and EFS amounted to 93 % and 88 %, respectively. High survival rates of patients with EATL were achieved with the use of high-dose chemotherapy according to the LB-M-04 program followed by auto-HSCT in the first line of therapy: 5-year OS and EFS amounted to 79 % and 74 %, respectively. The positive role of AITL maintenance therapy has been shown: 5-year OS and EFS during its implementation amounted to 75 % and 49 % versus 41 % and 20 % in the absence of it. In the protocols for the treatment of extranodal NK/T cell lymphoma, radiation therapy was used in the first line of therapy, 5-year OS and EFS were 60 % and 42 %, respectively. The role of autologous hematopoietic stem cell transplantation (auto-HSCT) in all PTCL was evaluated: 5-year OS and EFS were 82 % and 58 % compared with 67 % and 49 % without auto-HSCT. The transplantation of allogeneic hematopoietic stem cells (allo-HSCT), even in the treatment of relapses of the disease, has shown its effectiveness: 9 out of 11 patients are alive and remain in remission of the disease.


  • Successful Treatment of Acquired Thrombotic Thrombocytopenic Purpura With Caplacizumab Combined With Plasma Exchanges and Immune Suppression in 3 Children

    by Irina I. Kalinina, Khristina S. Antonova, Pavel V. Avdonin, Elizaveta E. Klebanova, Natalia N. Kotskaya, Elena E. Kurnikova, Alexandra D. Shutova, Victor E. Matveev, Alexey A. Maschan

    Acquired thrombotic thrombocytopenic (aTTP) purpura is a life-threatening condition that can lead to devastating thromboembolic events. Recently, caplacizumab has been shown to rapidly restore platelet numbers and reduce the risk of severe end-organ damage when added to plasma exchanges (PEXs) and immunosuppression (IST). Here, we report the outcomes in 3 children with aTTP who were treated with caplacizumab in combination with PEXs and IST. In all 3 patients, platelet count increased to >15,000/mm3 in 24 h and normalized on day 4, whereas normalization of ADAMTS13 activity >50% and elimination of the inhibitor was achieved after 18 to 89 days. Epistaxis was observed in 2 patients and was the only side effect related to caplacizumab. Caplacizumab is a promising agent for first-line treatment of children with aTTP.


  • Open Access

    Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura — diagnostic difficulties and errors

    by G. M. Galstyan, E. E. Klebanova, S. Yu. Mamleeva, A. V. Grzhimolovskii, A. M. Kovrigina, V. N. Dvirnyk, D. K. Bessmertnyy, Z. T. Fidarova, A. L. Melikyan

       Introduction. When establishing a diagnosis of thrombotic thrombocytopenic purpura (TTP) for the first time, other diseases occurring with thrombocytopenia may be misdiagnosed.   Aim: to analyze diagnostic difficulties and errors of TTP.   Materials and methods. In total, 54 patients (44 women and 10 men) aged 18 to 83 years (median 33 years), who were diagnosed TTP from 2019 to 2023, were included in the study. Anamnesis, baseline hemoglobin, platelets, erythrocytes, lactate dehydrogenase and bilirubin serum concentrations, pre-established diagnoses, treatment, and outcomes were analyzed.   Results. Initially TTP was suspected only in 19 (35 %) patients. In 12 out of 54 patients immune thrombocytopenia (ITP) was initially misdiagnosed. Fisher-Evans syndrome was initially suspected in 3 patients. In sporadic cases, myelodysplastic syndrome, systemic lupus erythematosus / antiphospholipid syndrome, autoimmune hemolytic anemia were initially suspected. Among 15 women with associated with pregnancy TTP in 8 (53.3 %), HELLP syndrome was initially misdiagnosed. In total, 12 (22.2 %) of 54 TTP patients died. In 11/12 non-survival patients, TTP treatment was never started, because the doctors were waiting for the ADAMTS13 test results. A case report of Sequential Immune Thrombocytopenia (ITP) and TTP in the same Patient is described.   Conclusion. When thrombocytopenia is combined with hemolysis and in the absence of multiple organ pathology, it is difficult to differentiate ITP and TTP without examining the plasma activity of ADAMTS113. With a combination of ITP and TTP in the same patient, the study of ADAMTS13 plasma activity makes it possible to identify the leading mechanism of thrombocytopenia and choose treatment tactics.


  • Open Access

    Neurological disorders in patients with thrombotic thrombocytopenic purpura

    by G. M. Galstyan, E. E. Klebanova, S. Yu. Mamleeva, S. Yu. Fedorova, M. Yu. Drokov, G. A. Yatsyk

    Aim: to analyze the first neurological manifestation in patient with thrombotic thrombocytopenic purpura (TTP). Material and methods. The appeals from physicians who suspected TTP were included in the study. The neurological symptoms in 40 patients with TTP were also analyzed. Results. Among 208 physician appeals about the suspicion of TTP and the referral of plasma samples for testing of ADAMTS13 activity, there were 2% of neurologists. The diagnosis of TTP was confirmed in 40 patients. 9 (22.5%) had no neurological symptoms, and 31 (77.5%) had neurological disorders. Patients with neurological symptoms were older than patients without neurological symptoms (median 37 years and 31 years, p = 0.006). Neurological symptoms were less frequently observed in pregnancy-associated TTP (p = 0.008). Among neurological symptoms there were speech disorders (40%), headache (30%), cognitive deficits (32.5%), depression of consciousness (22.5%), paresis (25%), sensation disorders (20.5%), seizures (10%). Magnetic resonance imaging/computed tomography (MRI/CT) revealed ischemic stroke in 47.5%, hemorrhagic stroke in 15%. In 6 patients, despite neurological symptoms, no pathology was detected with MRI/CT. In 4 patients, in the absence of neurological symptoms, MRI/CT revealed ischemic foci in the brain. 8 patients died: 2 patients died from sepsis, 6 - from ischemic stroke. In surviving patients, neurological symptoms regressed after remission. Conclusion. Neurological symptoms are detected in most patients with TTP. Brain MRI/CT should be performed in all patients with TTP


  • Open Access

    Thrombotic thrombocytopenic purpura in pregnancy. Giving birth or not giving birth, that is the question

    by G. M. Galstyan, R. G. Shmakov, Е. Е. Klebanova, V. V. Troitskaya, V. N. Dvirnyk, V. L. Surin, O. S. Pshenichnikova, Yu. M. Pozdnyakova, E. S. Polushkina, T. V. Gaponova, et al.

    Introduction. Pregnancy is one of the most frequent triggers of congenital and acquired forms of thrombotic thrombocytopenic purpura (TTP).Aim — to develop tactics for the treatment of pregnant women with TTP.Results. TTP was associated with pregnancy in 55.5 % of all cases of TTP in women. In 5 pregnancies in which the diagnosis of TTP was known before pregnancy, or established in the early stages, TTP was treated throughout the pregnancy. In the congenital form, plasma transfusions were performed once every two weeks until the 20th week of pregnancy, or weekly, if thrombocytopenia < 150 × 109 /L persisted. Plasma transfusions were performed weekly after the 20th week with the goal of achieving clinical remission. With acquired TTP, glucocorticosteroids and plasma exchanges were used as treatment, in 1 case — rituximab, with the aim of achieving a clinical remission and an ADAMTS13 activity > 20 %. In this group of pregnant women, 1 caesarean section was performed and there were 4 cases of vaginal deliveries, with a total of 5 children being born with an average Apgar score of 7.5. In 7 pregnancies in which TTP fi rst manifested late, leading to a delayed diagnosis, preventive and curative measures were not carried out before delivery. In this group there were 2 abortions of pregnancy, 5 surgical deliveries, 3 cases of preeclampsia, 3 acute cerebral circulatory disorders, 1 intraabdominal bleeding, 1 case of acute renal failure, with two women undergoing mechanical ventilation. There was 1 case of antenatal fetal death, with a total of 4 children being born, who were assessed on the Apgar scale with an average of 5 points.Conclusion. Timely diagnosis as well as ongoing therapeutic and preventive measures help to avoid complications during childbirth in pregnant women with TTP.